CLDX
Companies
NASDAQ
Celldex Therapeutics Inc.
Health Care
$20.82
-$4.45 (-17.61%)
Price Chart
Overview
About CLDX
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
Market Cap
$2.3B
Volume
15.8M
Avg. Volume
15.9M
P/E Ratio
-6.343653
Dividend Yield
0.00%
Employees
161.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.75
Moderate Correlation
Volatility
High (0.53)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, CLDX shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$2.3B
Volume15.8M
P/E Ratio-6.34
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 9, 2025Related Securities
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025